Literature DB >> 17316414

Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.

Kei Kushitani1, Yukio Takeshima, Vishwa Jeet Amatya, Osamu Furonaka, Akio Sakatani, Kouki Inai.   

Abstract

The distinction between epithelioid mesothelioma and lung adenocarcinoma remains an important diagnostic challenge for surgical pathologists. The aim of the present study was to select a limited and appropriate panel of antibodies that can differentiate between epithelioid mesothelioma and lung adenocarcinoma. Specimens of 90 epithelioid mesotheliomas and 51 lung adenocarcinomas obtained from Japanese cases were examined using calretinin, WT1, AE1/AE3, CAM5.2, cytokeratin (CK) 5/6, vimentin, epithelial membrane antigen (EMA), thrombomodulin, CEA, CA19-9, and CA125. Ninety-six percent of epithelioid mesotheliomas were positive for calretinin; 99% for WT1; 100% for AE1/AE; 97% for CAM5.2; 70% for CK 5/6; 91% for vimentin; 96% for EMA; 71% for thrombomodulin; 77% for mesothelin; 7% for CEA; 17% for CA19-9; and 85% for CA125. In contrast, 33% of lung adenocarcinomas were positive for calretinin; 16% for WT1; 100% for AE1/AE3, CAM5.2, and EMA; 41% for CK 5/6; 47% for vimentin; 20% for thrombomodulin; 69% for mesothelin; 98% for CEA; 73% for CA19-9; and 80% for CA125. For distinguishing between epithelioid mesothelioma and lung adenocarcinoma, the combination of CEA, calretinin and each WT1 or thrombomodulin was suggested to be the best panel of immunohistochemical markers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316414     DOI: 10.1111/j.1440-1827.2007.02080.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  22 in total

1.  Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Authors:  Masanori Fujii; Nobukazu Fujimoto; Akio Hiraki; Kenichi Gemba; Keisuke Aoe; Shigeki Umemura; Hideki Katayama; Nagio Takigawa; Katsuyuki Kiura; Mitsune Tanimoto; Takumi Kishimoto
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

2.  Pathology of mesothelioma.

Authors:  Kouki Inai
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.

Authors:  Lucian R Chirieac; Geraldine S Pinkus; Jack L Pinkus; John Godleski; David J Sugarbaker; Joseph M Corson
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

Review 4.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.

Authors:  Till Plönes; Mitja Fischer; Kerstin Höhne; Hiromi Sato; Joachim Müller-Quernheim; Gernot Zissel
Journal:  Pathol Oncol Res       Date:  2017-01-04       Impact factor: 3.201

6.  Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

Authors:  S Cedrés; M A Montero; E Zamora; A Martínez; P Martínez; L Fariñas; A Navarro; D Torrejon; A Gabaldon; S Ramon Y Cajal; E Felip
Journal:  Clin Transl Oncol       Date:  2013-12-10       Impact factor: 3.405

7.  [Pseudo-mesotheliomatous adenocarcinoma of the lung].

Authors:  K Aumann; J Günter; N Freudenberg
Journal:  Pathologe       Date:  2010-07       Impact factor: 1.011

8.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Authors:  Raffit Hassan; Charles Schweizer; Kun F Lu; Barbara Schuler; Alan T Remaley; Susan C Weil; Ira Pastan
Journal:  Lung Cancer       Date:  2009-09-09       Impact factor: 5.705

10.  Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Authors:  Frieder Bauss; Martin Lechmann; Ben-Fillippo Krippendorff; Roland Staack; Frank Herting; Matthias Festag; Sabine Imhof-Jung; Friederike Hesse; Marc Pompiati; Gwendlyn Kollmorgen; Rita da Silva Mateus Seidl; Birgit Bossenmaier; Wilma Lau; Christian Schantz; Jan O Stracke; Ulrich Brinkmann; Masanori Onda; Ira Pastan; Klaus Bosslet; Gerhard Niederfellner
Journal:  Mol Oncol       Date:  2016-07-14       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.